Carl Regillo

About Carl Regillo

“My main clinical research focus has been to help develop sustained drug delivery systems for common retinal conditions, such as neovascular AMD, diabetic retinopathy, and diabetic macula edema. Considerable strides have been made with the port delivery system approach being FDA approved now for all three indications, along with further refinements in the surgical approach to reduce surgery and device-related adverse events.

“There has also been substantial progress in advancing tyrosine kinase inhibitor small molecules incorporated into injectable bioerodible inserts to give six or more months of an anti-VEGF-like therapeutic effect, with successful phase 2 study results in both neovascular AMD and DME. These products are now well into global phase 3 registration studies.

“Lastly, there has been more progress with anti-VEGF gene therapy for sustained delivery with both intravitreal and subretinal delivered products in phase 3 clinical trials. The next 1-2 years will be very exciting, with topline data readouts of many of these studies and the potential for additional approved maintenance phase therapy options for patients with the promise of better real-world visual outcomes with these common conditions.”